Table 3 Multivariate analyses for overall survival and scoring system
Factors independently prognostic of shorter overall survival | HR | 95%CI | p value | |
Training patient set (n = 903) | ||||
Non-matched therapy | 1.20 | 1.04 | 1.38 | 0.01 |
Performance status > 1 | 2.52 | 1.94 | 3.28 | < 0.001 |
Liver metastases | 1.52 | 1.31 | 1.77 | < 0.001 |
LDH > ULN | 1.66 | 1.42 | 1.93 | < 0.001 |
PI3K/AKT/mTOR pathway alterations | 1.18 | 1.01 | 1.37 | 0.03 |
Validation patient set (n = 404) | ||||
Non-matched therapy | 1.59 | 1.29 | 1.96 | < 0.001 |
Performance status > 1 | 2.21 | 1.53 | 3.20 | < 0.001 |
Liver metastases | 1.35 | 1.07 | 1.69 | 0.01 |
LDH > ULN | 1.70 | 1.36 | 2.12 | < 0.001 |
PI3K/AKT/mTOR pathway alterations | 1.43 | 1.14 | 1.80 | 0.002 |
All patients (N = 1307) | ||||
Non-matched therapy | 1.32 | 1.17 | 1.48 | < 0.001 |
Performance status > 1 | 2.38 | 1.93 | 2.95 | < 0.001 |
Liver metastases | 1.44 | 1.28 | 1.63 | < 0.001 |
LDH > ULN | 1.66 | 1.46 | 1.88 | < 0.001 |
PI3K/AKT/mTOR pathway alterations | 1.25 | 1.10 | 1.42 | < 0.001 |
Scoring system for survival model | ||||
Factors | HR | Score | ||
Matched therapy | ||||
Yes | 1.00 | 0 | ||
No | 1.32 | 1 | ||
Performance status | ||||
0–1 | 1.00 | 0 | ||
2–3 | 2.38 | 2 | ||
Liver metastases | ||||
No | 1.00 | 0 | ||
Yes | 1.44 | 1 | ||
LDH > ULN | ||||
No | 1.00 | 0 | ||
Yes | 1.66 | 1 | ||
PI3K/AKT/mTOR pathway alterations | ||||
No | 1.00 | 0 | ||
Yes | 1.25 | 1 | ||